menu
    • menu
    [{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Abbisko Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Abbisko Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ABK3376","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Abbisko Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pimicotinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbisko Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Abbisko Therapeutics

    Menu

    Abbisko Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pimicotinib Improves Outcomes in Tenosynovial Giant Cell Tumor Trial

                            Details : ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor.

                            Brand Name : ABSK021

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 11, 2024

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Abbisko’s CSF-1R Inhibitor Pimicotinib Receives Orphan Drug Designation

                            Details : ABSK021 (pimicotinib) is a selective CSF-1R inhibitor currently in phase 3 studies for treating inoperable tenosynovial giant cell tumors.

                            Brand Name : ABSK021

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 08, 2024

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimic...

                            Details : ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor (TGCT).

                            Brand Name : ABSK021

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 13, 2023

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck Strengthens Oncology Portfolio Through Commercialization Agreement with Abbisko for Phase III Asset, Pim...

                            Details : Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cel...

                            Brand Name : ABSK021

                            Molecule Type : Small molecule

                            Upfront Cash : $70.0 million

                            December 04, 2023

                            Lead Product(s) : Pimicotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABK3376,Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Shanghai Allist Pharmaceuticals

                            Deal Size : $187.9 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Shanghai's Abbisko Out-Licenses EGFR Candidate in Potentially Nine-Figure Deal

                            Details : The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.

                            Brand Name : ABK3376

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 01, 2023

                            Lead Product(s) : ABK3376,Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Shanghai Allist Pharmaceuticals

                            Deal Size : $187.9 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Abbisko Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $258.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules

                            Details : Under the terms of the Agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 18, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $258.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth